Innate reports Phase I data for monalizumab plus Imfinzi in CRC
Innate Pharma S.A. (Euronext:IPH) reported preliminary data from 37 evaluable patients with recurrent, metastatic, microsatellite-stable colorectal cancer (MSS-CRC) in an expansion portion of a Phase I trial showing that monalizumab (IPH2201) plus Imfinzi durvalumab from AstraZeneca plc (LSE:AZN; NYSE:AZN) led to three partial responses and 11 cases of stable disease. The data were released in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago.
The open-label, international trial enrolled 15 patients with advanced solid tumors in five dose cohorts in a dose-escalation portion and 40 MSS-CRC patients in four dose cohorts in a dose-expansion portion. Innate said that AZ has initiated a dose-exploration portion with six dose cohorts in CRC patients who are also receiving standard of care (SOC) systemic therapy...